Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Summary

The purpose of the study is to learn about the safety, pharmacokinetics and antiviral activity of the study medicine (RV299) for the potential treatment of respiratory syncytial virus (RSV). RSV is a highly contagious virus that can lead to serious lung infections in patients with reduced ability to fight infection. Most vulnerable populations include babies, the elderly and patients that have received a bone marrow transplant.

Timeline

Start

2022-08-08

Primary completion

2022-12-02

Completion

2022-12-02

Outcome

Met primary endpoint

registry analysis (other test); RV299 vs Placebo; p = 0.0009; Difference in Least Square Mean -312.28 (95% CI -489.17 to -135.38); ANCOVA NCT06067191 ↗

Drugs

Indications